Lilly And China's Hisun Complete Technology Transfer For Antibiotic Capreomycin For TB
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Eli Lilly and Chinese active pharmaceutical ingredient provider Hisun recently announced the completion of a technology transfer under which Lilly transferred technology to Hisun to produce finished products and API of its tuberculosis drug capreomycinYou may also be interested in...
China’s Hisun Gets Capreomycin WHO Prequalification
Hisun’s pre-qualification approval for capreomycin to treat second-line active tuberculosis cases may help bring costs down for a drug increasingly in demand as multi-drug resistant patients multiply worldwide.
Lifestyle Disease Trend Continues In Asia - WHO Epidemiology Report
HONG KONG - Growing economies, improved diets and access to healthcare are having a positive effect on health across Asia, but the incidence of infectious diseases remains stubbornly high and the impact is compounded by rises in non-communicable lifestyle diseases. The latest set of statistical data from the World Health Organization suggests more and more countries are forced to tackle both simultaneously, and global and local pharma companies are racing to fill unmet needs
Lifestyle Disease Trend Continues In Asia - WHO Epidemiology Report
HONG KONG - Growing economies, improved diets and access to healthcare are having a positive effect on health across Asia, but the incidence of infectious diseases remains stubbornly high and the impact is compounded by rises in non-communicable lifestyle diseases. The latest set of statistical data from the World Health Organization suggests more and more countries are forced to tackle both simultaneously, and global and local pharma companies are racing to fill unmet needs
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports